115 results found.

Non Small Cell Lung Cancer (NSCLC) Clinical Trial using MK-3475; Docetaxel

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer.
MK-3475; Docetaxel

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
afatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
Afatinib

Non-Small Cell Lung Cancer, Anemia, Cancer, or Lung Cancer Clinical Trial using darbepoetin alfa 500 mcg Q3W; placebo

Amgen - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.
darbepoetin alfa 500 mcg Q3W; placebo

Cancer, Solid Tumor Clinical Trial using MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma.
MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Recurrent Non-small Cell Lung Cancer, or Stage IV Non-small Cell Clinical Trial using cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy.
cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

Stage III Non-small Cell Lung Cancer Clinical Trial using 1 MRI scan

UMC Utrecht - Recruiting 18 years or older.
- MRI for Radiotherapy Treatment Planning of Stage III NSCLC: an MRI Optimization Study in Healthy Volunteers and Patients.
1 MRI scan

Non Small Cell Lung Cancer, ROS1 Proto Oncogene, or Crizotinib Clinical Trial using Crizotinib

OxOnc Development LP - Recruiting 18 years or older.
- Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus.
Crizotinib

Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lu Clinical Trial using positron emission tomography; computed tomography; intensity-modulated radiation therapy; carboplatin; paclitaxel

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- PET-Adjusted IMRT for NSCLC Trial (PAINT).
positron emission tomography; computed tomography; intensity-modulated radiation therapy; carboplatin; paclitaxel

Non-small Cell Lung Cancer Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment.
INC280

Non-small Cell Lung Cancer Clinical Trial using Nivolumab; Gemcitabine; Cisplatin; Pemetrexed; Paclitaxel; Carboplatin; Bevacizumab; Erlotinib; Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).
Nivolumab; Gemcitabine; Cisplatin; Pemetrexed; Paclitaxel; Carboplatin; Bevacizumab; Erlotinib; Ipilimumab

Non-Small Cell Lung Cancer Clinical Trial using erlotinib; placebo; onartuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION.
erlotinib; placebo; onartuzumab

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of First-line Maintenance Tarceva vs Tarceva at the Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following 4 Cycles of Platinum-based Chemotherapy.
erlotinib [Tarceva]; Placebo

Solid Tumour,, Breast Cancer,, Metastatic Melanoma,, or Non-small Clinical Trial using F16IL2 in combination with paclitaxel

Philogen S.p.A. - Recruiting 18 years or older.
- Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.
F16IL2 in combination with paclitaxel

Non Small Cell Lung Cancer Clinical Trial using DCE-MRI scan; Stereotactic Body Radiation Therapy; 4D-CT scan

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Feasibility Study of the Utility of Pulmonary Dynamic Contrast Enhanced MRI for Assessment of Tumor Response and Lung Injury and for Treatment Planning for Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer.
DCE-MRI scan; Stereotactic Body Radiation Therapy; 4D-CT scan

NSCLC Clinical Trial using afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)

Samsung Medical Center - Recruiting 20 years or older.
- A Phase Ib Study of Afatinib Plus Nimotuzumab in Non-small Cell Lung Cancer Patients Who Progressed With Reversible EGFR TKI.
afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1).
Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, or Stage Clinical Trial using counseling intervention; questionnaire administration; quality-of-life assessment

Stanford University - Recruiting N/A or older.
- Intervention Development for Anxiety in Metastatic NSCLC Patients and Their Caregivers.
counseling intervention; questionnaire administration; quality-of-life assessment

Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lu Clinical Trial using HPPH; therapeutic conventional surgery; photodynamic therapy

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) With Temoporfin in Patients With Resectable Primary Non-Small Cell Lung Cancer (NSCLC) With Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease.
HPPH; therapeutic conventional surgery; photodynamic therapy

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Clinical Trial

AstraZeneca - Recruiting 18 years or older.
- A Diagnostic Study of European and Japanese Advanced NSCLC Patients to Evaluate Suitable Sample Types for EGFR Testing,.

Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lu Clinical Trial using photon beam radiation therapy; proton beam radiation therapy; paclitaxel; carboplatin; etoposide; cisplatin; quality-of-life assessment; questionnaire administration

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
photon beam radiation therapy; proton beam radiation therapy; paclitaxel; carboplatin; etoposide; cisplatin; quality-of-life assessment; questionnaire administration

Non-Small Cell Lunch Cancer Clinical Trial using BKM120; placebo; Carboplatin; Paclitaxel

Novartis - Recruiting 18 years or older.
- A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology.
BKM120; placebo; Carboplatin; Paclitaxel

Lung Cancer, Non-Small Cell Clinical Trial using Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer.
Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A; Placebo

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC).
selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

Solid Tumors, Cancer, or NSCLC Clinical Trial using cabozantinib capsules; cabozantinib tablets

Exelixis - Recruiting 20 years or older.
- Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors.
cabozantinib capsules; cabozantinib tablets

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line..

Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Lar Clinical Trial using PI3K inhibitor BKM120; pemetrexed disodium; carboplatin; laboratory biomarker analysis; pharmacological study; quality-of-life assessment

City of Hope Medical Center - Recruiting 18 years or older.
- Phase I Trial of BKM120 in Combination With Carboplatin and Pemetrexed in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).
PI3K inhibitor BKM120; pemetrexed disodium; carboplatin; laboratory biomarker analysis; pharmacological study; quality-of-life assessment

Squamous Non-small Cell Lung Cancer Clinical Trial using Buparlisib; Buparlisib matching placebo; Docetaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer.
Buparlisib; Buparlisib matching placebo; Docetaxel

NSCLC (Non-small Cell Lung Cancer) Clinical Trial using Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Pfizer - Recruiting 18 years to 70 years.
- Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated East Asian Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Systemic Anaplastic Large-Cell Lymphoma, Neoplasms, Anaplastic Ly Clinical Trial using PF-02341066; Rifampin; Ketoconazole

Pfizer - Recruiting 18 years or older.
- Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer.
PF-02341066; Rifampin; Ketoconazole

Non-Small Cell Lung Carcinoma Clinical Trial using CV9202

CureVac GmbH - Recruiting 18 years or older.
- An Exploratory, Open-label Phase Ib Study of RNActiver-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor.
CV9202

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region..

Advanced NSCLC, or First Line Treatment Clinical Trial using Exercise Intervention; Care-Management-Phone-Calls

German Cancer Research Center - Recruiting 18 years or older.
- Physical Exercise Program in Lung Cancer Patients With Non-operable Disease Undergoing Palliative Treatment.
Exercise Intervention; Care-Management-Phone-Calls

Non Small Cell Lung Cancer Clinical Trial

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy - Recruiting 18 years or older.
- An Exploratory Study of the Performance of Mass-Spectrometry Based Test Veristrat in Prediction of Benefit of First Line NSCLC Patients From Treatment With Standard Chemotherapy Regimens.

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; gemcitabine; cisplatin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multiple Center, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV NSCLC Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumor.
erlotinib [Tarceva]; gemcitabine; cisplatin

Non-small Cell Lung Cancer Clinical Trial using Induction chemotherapy and concurrent radiation; Consolidation: Radiation therapy to metastatic sites

Leo W. Jenkins Cancer Center - Recruiting 18 years or older.
- A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent.
Induction chemotherapy and concurrent radiation; Consolidation: Radiation therapy to metastatic sites

Lung Cancer Clinical Trial using Afatinib; Radiation; Cisplatin; Pemetrexed; Surgery

Massachusetts General Hospital - Recruiting 18 years or older.
- Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial.
Afatinib; Radiation; Cisplatin; Pemetrexed; Surgery

Lung Cancer - Non Small Cell Clinical Trial using Ipilimumab; Placebo; Paclitaxel; Carboplatin

Bristol-Myers Squibb - Recruiting 18 years or older.
- Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC).
Ipilimumab; Placebo; Paclitaxel; Carboplatin

Non-small Cell Lung Cancer Patients Clinical Trial using 18F-FDG-PET scan

University of Aarhus - Recruiting 18 years or older.
- Early Changes in 18F-fluorodeoxyglucose Positron Emissions Tomography (18F-FDG-PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI).
18F-FDG-PET scan

Lung Cancer, or Non-Small Cell Lung Cancer Clinical Trial using MEK162; Erlotinib

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- A Phase I/IB Trial of MEK162 in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS or EGFR Mutation.
MEK162; Erlotinib

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Efficacy and Safety of erLotinib (Tarcevar ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT.

Lung Cancer, or Metastatic Cancer Clinical Trial using computed tomography; 3-dimensional conformal radiation therapy; fludeoxyglucose F 18; radiation therapy treatment planning/simulation

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy.
computed tomography; 3-dimensional conformal radiation therapy; fludeoxyglucose F 18; radiation therapy treatment planning/simulation

Non-small Cell Lung Cancer (NSCLC) Clinical Trial using Endocutter

Ethicon Endo-Surgery - Recruiting 18 years or older.
- A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures.
Endocutter

Non Small Cell Lung Cancer (NSCLC) Clinical Trial using SPI-1620 & Docetaxel; Docetaxel

Spectrum Pharmaceuticals, Inc - Recruiting 18 years or older.
- A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy.
SPI-1620 & Docetaxel; Docetaxel

Non-small-cell Lung Cancer Clinical Trial

Guangdong Association of Clinical Trials - Recruiting 18 years or older.
- A Prospective Epidemiologic and Clinical Feature Study of Non-Small Cell Lung Cancer (NSCLC) Patients With ALK Positive in China.

Squamous Non Small Cell Lung Cancer Clinical Trial using Necitumumab; Paclitaxel; Carboplatin

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC).
Necitumumab; Paclitaxel; Carboplatin

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib.
LY2875358; Erlotinib

Lung Cancer Clinical Trial using Minocycline; Placebo; Questionnaires

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer.
Minocycline; Placebo; Questionnaires

Squamous Non-small Cell Lung Cancer Clinical Trial using Necitumumab; Gemcitabine; Cisplatin

Eli Lilly and Company - Recruiting 20 years or older.
- An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC).
Necitumumab; Gemcitabine; Cisplatin

Non Small Cell Lung Cancer Clinical Trial using Gefitinib; Tremelimumab

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients.
Gefitinib; Tremelimumab

Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, or Metastatic Clinical Trial using Cabazitaxel-XRP6258

University of Alabama at Birmingham - Recruiting 19 years or older.
- Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients.
Cabazitaxel-XRP6258

NSCLC, Non-small Cell Lung Cancer, or Lung Cancer Clinical Trial using MEDI4736; Tremelimumab

MedImmune LLC - Recruiting 18 years or older.
- A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer.
MEDI4736; Tremelimumab

Non Small Cell Lung Cancer Clinical Trial using I-131-NM404; I124-NM404

University of Wisconsin, Madison - Recruiting 18 years or older.
- NM404 as an Imaging Agent in Patients With Non-small Cell Lung Cancer (NSCLC).
I-131-NM404; I124-NM404

Non Small Cell Lung Cancer Clinical Trial

Maastricht Radiation Oncology - Recruiting 18 years or older.
- In Silico Clinical Trial, Comparing State of the Art Photon Modalities With Proton and 12C-ion Therapy for Stage I NSCLC: A Multicentric ROCOCO Planning Study Based on a Reference Dataset of Patients.

Skin Rash, or Lung Cancer Clinical Trial using Tetracycline

Instituto Nacional de Cancerologia de Mexico - Recruiting 18 years or older.
- Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992.
Tetracycline

NSCLC Clinical Trial using Radiotherapy

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Dose Escalation by Boosting Radiation Dose Within the Primary Tumor on the Basis of a Pre-treatment FDG-PET-CT Scan in Stage IB, II and III NSCLC: a Randomized Phase II Trial.
Radiotherapy

Non-small Cell Lung Cancer Clinical Trial using Dacomitinib

Pfizer - Recruiting 18 years or older.
- Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced NSCLC.
Dacomitinib

Non-small Cell Lung Cancer(NSCLC) Clinical Trial using erlotinib; docetaxel

National Taiwan University Hospital - Recruiting 18 years or older.
- An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation..
erlotinib; docetaxel

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using PET/CT

National Cancer Institute, Naples - Recruiting 18 years or older.
- Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC).
PET/CT

Non-small Cell Lung Cancer Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin

Biocad - Recruiting 18 years to 70 years.
- International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastinr (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients.
Bevacizumab; Paclitaxel; Carboplatin

Carcinoma, Non-Small-Cell Lung, or Neoplasm Metastasis Clinical Trial using 34 Gy in a single fraction; 54Gy 18Gy/fr. x 3 fractions; 50Gy (12 x 5 fr.s); 60Gy (7.5Gy x 8fr.)

Institut Catal… d'Oncologia - Recruiting 18 years or older.
- Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases.
34 Gy in a single fraction; 54Gy 18Gy/fr. x 3 fractions; 50Gy (12 x 5 fr.s); 60Gy (7.5Gy x 8fr.)

Non-small Cell Lung Cancer Clinical Trial using MSC2156119J; Gefitinib; Pemetrexed; Cisplatin

Merck KGaA - Recruiting 18 years or older.
- A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare MSC2156119J Combined With Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First-line Gefitinib.
MSC2156119J; Gefitinib; Pemetrexed; Cisplatin

Advanced Malignancies, Non-small Cell Lung Cancer Clinical Trial using MGCD265+erlotinib; MGCD265+docetaxel

MethylGene Inc. - Recruiting 18 years or older.
- A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC).
MGCD265+erlotinib; MGCD265+docetaxel

Self Efficacy, or Drug Toxicity Clinical Trial using Erlotinib or Gefitinib

Anhui Medical University - Recruiting 18 years to 75 years.
- An Open,Multi Center Trial to Evaluate the Efficacy and Safety of High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced Non-Small Cell Lung Cancer Patients After Failure of Standard Dose EGFR-TKIs.
Erlotinib or Gefitinib

Brain Metastases From Non-small Cell Lung Cancer Clinical Trial using Veliparib; Placebo

AbbVie - Recruiting 18 years or older.
- A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer.
Veliparib; Placebo

NSCLC Clinical Trial

Maastricht Radiation Oncology - Recruiting N/A or older.
- In Silico Clinical Trial on Re-irradiation Lung Cancer, Comparing Photon, Proton and 12C-ion Therapy: A Multicentric ROCOCO Planning Study Based on a Reference Dataset of Patients..

Non-small Cell Lung Carcinoma Clinical Trial using None: Questionnaire Study

University Health Network, Toronto - Recruiting 18 years or older.
- Prospective Observational Study Of Patients With Asymptomatic Centrally Located Advanced NSCLC Who Are Not Suitable For Curative Treatment.
None: Questionnaire Study

Lung Cancer, or Non-small Cell Lung Cancer (NSCLC) Clinical Trial using Dasatinib - 1A; Afatinib - 1A; Dasatinib - 1B; Afatinib - 1B

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC).
Dasatinib - 1A; Afatinib - 1A; Dasatinib - 1B; Afatinib - 1B

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using Gemcitabine; Pemetrexed; Cisplatin

National Cancer Institute, Naples - Recruiting 70 years or older.
- A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC..
Gemcitabine; Pemetrexed; Cisplatin

Non-Small Cell Lung Cancer Clinical Trial using Icotinib

Zhejiang Beta Pharma Inc. - Recruiting 70 years to 80 years.
- An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation.
Icotinib

NSCLC Clinical Trial using Icotinib of routine dose; Icotinib of high dose

Zhejiang Beta Pharma Inc. - Recruiting 18 years to 75 years.
- An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease.
Icotinib of routine dose; Icotinib of high dose

Non Small Cell Lung Cancer Clinical Trial using Bevacizumab; recombinant human endostatin

Zhejiang University - Recruiting 18 years to 75 years.
- Phase II Study of Intrapleural Administration of Bevacizumab Versus Recombinant Human Endostatin (Endostar) for Refractory Malignant Pleural Effusions in Advanced Non-small Cell Lung Cancer (NSCLC).
Bevacizumab; recombinant human endostatin

Non Small Cell Lung Cancer Clinical Trial using EGFR tyrosine kinase inhibitor; EGFR tyrosine kinase inhibitor with chemotherapy

Zhejiang University - Recruiting 18 years to 75 years.
- Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC).
EGFR tyrosine kinase inhibitor; EGFR tyrosine kinase inhibitor with chemotherapy

Non-small Cell Lung Cancer Clinical Trial using Monosialoganglioside(GM1); normal saline

Sun Yat-sen University - Recruiting N/A or older.
- A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients..
Monosialoganglioside(GM1); normal saline

Non Small Cell Lung Cancer Clinical Trial using Afatinib

Massachusetts General Hospital - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation.
Afatinib

Non Small Cell Lung Cancer, or Chronic Obstructive Pulmonary Dise Clinical Trial

University of Virginia - Recruiting 18 years or older.
- The Use of Circulating Tumor Cells in Non-Small Cell Lung Cancer: Novel Isolation Methods and Clinical Applications.

EGFR Positive Non-small Cell Lung Cancer Clinical Trial using Dacomitinib (PF-00299804); Gefitinib

SFJ Pharmaceuticals, Inc. - Recruiting 18 years or older.
- ARCHER 1050: A Randomized, Open Label Phase 3 Efficacy and Safety Study Of Dacomitinib (PF-00299804) Vs. Gefitinib For The First-Line Treatment Of Locally Advanced or Metastatic NSCLC In Subjects With EGFR Activating Mutations.
Dacomitinib (PF-00299804); Gefitinib

Lung Neoplasms Clinical Trial using Sublobar Resection; Stereotactic Body Radiotherapy (SBRT)

Mayo Clinic - Recruiting 18 years or older.
- Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC).
Sublobar Resection; Stereotactic Body Radiotherapy (SBRT)

Non-small-cell Lung Cancer Clinical Trial using Pemetrexed; Bevacizumab

Hellenic Oncology Research Group - Recruiting 18 years or older.
- Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC).
Pemetrexed; Bevacizumab

Non-small-cell Lung Cancer Clinical Trial using Docetaxel; Bevacizumab

Hellenic Oncology Research Group - Recruiting 18 years or older.
- Docetaxel Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC.
Docetaxel; Bevacizumab

Lung Cancer Clinical Trial using EBUS-TBNA

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Diagnostic Utility of Endobronchial Ultrasound Guided Mediastinal Lymph Node Sampling in Clinical Stage I and II Non Small Cell Lung Cancer.
EBUS-TBNA

Non-small Cell Lung Cancer Clinical Trial using Blood samples

Maastricht Radiation Oncology - Recruiting N/A or older.
- Use of Blood Biomarkers to Predict Overall Survival for Non-Small-cell Lung Cancer (NSCLC) Patients Treated With (Chemo)Radiotherapy..
Blood samples

Non-small Cell Lung Cancer Clinical Trial using Nimotuzumab and TP regimen; TP regimen

Tianjin Medical University Cancer Institute and Hospital - Recruiting 18 years to 70 years.
- The Study of Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for Patient With the Advanced Non-small Cell Lung Cancer( NSCLC).
Nimotuzumab and TP regimen; TP regimen

Non-small Cell Lung Cancer Clinical Trial using gefitinib

Guangdong Association of Clinical Trials - Recruiting 18 years to 75 years.
- Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study.
gefitinib

Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Non-small-ce Clinical Trial using MORAb-066

Morphotek - Recruiting 18 years or older.
- A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies.
MORAb-066

Recurrent Non-small Cell Lung Cancer, or Stage IV Non-small Cell Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase II Study of Weekly ABRAXANEr (Nab-paclitaxel) for Patients With Advanced NSCLC With EGFR Mutations Following Front-line Therapy With EGFR Tyrosine Kinase Inhibitors.
paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Nec Clinical Trial using 18F-fluoromisonidazole; fluorescence angiography; laboratory biomarker analysis; infrared thermography; magnetic resonance imaging; therapeutic conventional surgery; [18F]-ML-10; fludeoxyglucose F 18; rubidium Rb-82

National Cancer Institute (NCI) - Recruiting N/A or older.
- Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation.
18F-fluoromisonidazole; fluorescence angiography; laboratory biomarker analysis; infrared thermography; magnetic resonance imaging; therapeutic conventional surgery; [18F]-ML-10; fludeoxyglucose F 18; rubidium Rb-82

Lung Cancer Clinical Trial using carboplatin; cisplatin; gemcitabine hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).
carboplatin; cisplatin; gemcitabine hydrochloride

Non-small-cell Lung Cancer Clinical Trial using Icotinib+WBRT

Zhejiang Beta Pharma Inc. - Recruiting 18 years to 75 years.
- A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases.
Icotinib+WBRT

Non-small Cell Lung Cancer, Radiation Therapy, Locally Advanced D Clinical Trial using mid-position radiation strategy; ITV

Centre Leon Berard - Recruiting 18 years or older.
- Randomized Phase 2 Study Evaluating the Interest of Mid-position Strategy Versus ITV (Internal Target Volume) Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-resected Non-small Cell Lung Carcinoma (NSCLC)..
mid-position radiation strategy; ITV

Stage III Non-small Cell Lung Cancer Clinical Trial using Chemotherapy; ERBITUX; Radiotherapy

Intergroupe Francophone de Cancerologie Thoracique - Recruiting 18 years to 70 years.
- Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC).
Chemotherapy; ERBITUX; Radiotherapy

NSCLC Clinical Trial using Olaparib; Cisplatin; Radiation

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma.
Olaparib; Cisplatin; Radiation

NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC Clinical Trial using Gefitinib and Metformin; Gefitinib and placebo

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University - Recruiting 18 years to 75 years.
- A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer.
Gefitinib and Metformin; Gefitinib and placebo

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, or S Clinical Trial using Cisplatin; Pemetrexed; Gemcitabine

Western Regional Medical Center - Recruiting 18 years or older.
- Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer.
Cisplatin; Pemetrexed; Gemcitabine

Non-small Cell Lung Cancer (NSCLC) Clinical Trial using VATS for confirmed non-small cell lung cancer (NSCLC)

Ethicon Endo-Surgery (Europe) GmbH - Recruiting 18 years or older.
- Real World Outcomes of Video-Assisted Thoracoscopic Surgery for Lung Cancer Using ECHELON FLEXT Powered ENDOPATHr Stapler: a Prospective European Multicenter Study.
VATS for confirmed non-small cell lung cancer (NSCLC)

Lung Cancer Clinical Trial using Pazopanib

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab.
Pazopanib

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial

Chonnam National University Hospital - Recruiting 19 years to 80 years.
- Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib.

Non-small Cell Lung Cancer Clinical Trial using Gefitinib

Asan Medical Center - Recruiting 19 years or older.
- First Line Gefitinib Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) by the FDG-PET Metabolic Response.
Gefitinib

Non Small Cell Lung Cancer Clinical Trial using decitabine in combination with genistein

Uman Pharma - Recruiting 18 years to 75 years.
- A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects.
decitabine in combination with genistein

NSCLC Clinical Trial using Pemetrexed 500mg/m2 iv; Pemetrexed 500mg/m2 iv and Gefitinib 250 mg

Taipei Veterans General Hospital, Taiwan - Recruiting 20 years or older.
- An Open Label, Randomized, Multicenter, Phase II Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Advanced (Stage IV) EGFR Mutation Negative or T790M Single Mutation Nonsquamous NSCLC Who Respond to 4 Cycles of Pemetrexed/ Platinum as First-line Therapy.
Pemetrexed 500mg/m2 iv; Pemetrexed 500mg/m2 iv and Gefitinib 250 mg

Non-small Cell Lung Cancer Stage IIIB, or Toxicity Due to Chemoth Clinical Trial using chemotherapy & WBH

Xijing Hospital - Recruiting 18 years to 75 years.
- A Randomized Contrasted Polycentric Clinical Study About Chemotherapy Combined With Whole-body Hyperthermia(WBH)to Treat Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC).
chemotherapy & WBH

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous, or Carcinoma Clinical Trial using Docetaxel; Oxaliplatin

Korean South West Oncology Group - Recruiting 18 years or older.
- A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment.
Docetaxel; Oxaliplatin

Non-small Cell Lung Cancer Clinical Trial using Gefitinib

ZhuGuangYing - Recruiting 18 years to 75 years.
- A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations.
Gefitinib

Nonsmall Cell Lung Cancer Clinical Trial using Radiosurgery; Observation

Samsung Medical Center - Recruiting 18 years or older.
- Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC).
Radiosurgery; Observation

NSCLC, or Non Small Cell Lung Cancer Clinical Trial using Cesium-131 Brachytherapy Seed

IsoRay Medical, Inc. - Recruiting N/A or older.
- Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC.
Cesium-131 Brachytherapy Seed

Carcinoma, Non-Small-Cell Lung Clinical Trial using erlotinib plus docetaxel or pemetrexed; erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis - Recruiting 18 years or older.
- A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study).
erlotinib plus docetaxel or pemetrexed; erlotinib

Non-small Cell Lung Cancer Clinical Trial using Prophylactic cranial irradiation; Erlotinib /Gefitinib

Zhejiang Cancer Hospital - Recruiting 18 years to 75 years.
- A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001).
Prophylactic cranial irradiation; Erlotinib /Gefitinib

Lung Cancer Clinical Trial using erlotinib hydrochloride; stereotactic body radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Trial of Erlotinib (Tarcevar) in Combination With Stereotactic Body Radiation Therapy (SBRT) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
erlotinib hydrochloride; stereotactic body radiation therapy

Non-small Cell Lung Cancer Clinical Trial using Docetaxel and Cisplatin

Gyeongsang National University Hospital - Recruiting 18 years to 75 years.
- Phase II Study of Biweekly Schedule of Docetaxel and Cisplatin in Patients With Unresectable Non-small Cell Lung Cancer.
Docetaxel and Cisplatin

Lung Cancer Clinical Trial using erlotinib hydrochloride; sorafenib tosylate; DNA analysis; mutation analysis; polymerase chain reaction; protein analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens.
erlotinib hydrochloride; sorafenib tosylate; DNA analysis; mutation analysis; polymerase chain reaction; protein analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis

Advanced Non-Small Cell Lung Cancer Clinical Trial using Pemetrexed; Pemetrexed plus carboplatin

Gruppo Oncologico Italiano di Ricerca Clinica - Recruiting 18 years or older.
- Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-small-cell Lung Cancer (NSCLC)..
Pemetrexed; Pemetrexed plus carboplatin

Non-small Cell Lung Cancer Clinical Trial using Pemetrexed; pemetrexed and erlotinib

Montefiore Medical Center - Recruiting 18 years or older.
- A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed and Erlotinib Versus Single Agent Pemetrexed in Patients With Progressive or Recurrent Non-Small Cell Lung Cancer (NSCLC).
Pemetrexed; pemetrexed and erlotinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Gemcitabine and Docetaxel

Hospital Arnau de Vilanova - Recruiting 18 years or older.
- Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2.
Gemcitabine and Docetaxel

Non Small Cell Lung Cancer Clinical Trial using erlotinib

Rigshospitalet, Denmark - Recruiting 18 years or older.
- A Phase II Study of Erlotinib and Predictive Markers as First-Line Treatment of Advanced Non-Small Cell Lung Cancer for Patients Unfit for Chemotherapy.
erlotinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Gefitinib; Radiation Therapy

Fudan University - Recruiting 18 years to 75 years.
- Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy.
Gefitinib; Radiation Therapy